Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases.  The Company's primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.

Current Report (Form 8-K | Period ending 2024-11-20)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Gilead Sciences (GILD US)

Current Report (Form 8-K | Period ending 2024-11-20)

424B5 | Prospectus

424B5 | Prospectus

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-11-06)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)